Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Any insights on this stock?
Any insights on why price and volume are up in premarket? I can’t find any news.
Thanks! When is the upcoming presentation? Do they have one prior to the extension deadline? Cash position may be fine but I thought they needed to attain a higher pps.
So, if a R/S is inevitable, why would investors buy in at 0.09? They could just wait after the R/S and buy in at a lower price as prices often fall after a RS. Maybe I’m missing something?
The primary end point was statistically significant. The secondary was not.
Now at 1.5 million shares traded in 30 mins. Hoping for some good news coming soon.
Up on very high volume, almost 500k in 15 minutes. Any news?
Great presentation today.
I meant to say they did a bad job on the PR. The results are positive.
Strange market reaction. Met primary. Bad PR though probably written by someone who is a researcher. The headline says that it met primary but didn't meet secondary. IN reality, the study wasn't powered to for statistical significance to detect differences in the secondary (meaning they didn't design it with the intent of measuring significance for this measure so they didn't recruit enough subjects) but the trends were encouraging. This is informative for the PH3 study. But it makes for bad PR since they haven't explained what they mean by it wasn't powered for significance.
We need news
I thought detailed results of their Phase II was due end of 2014?? No news, no explanation. Any one has further info?
Much higher volume today than we have seen in the past few weeks. Hopefully a sign of better things to come ....
Came across this video from 2012. Very encouraging.
Any insights on this stock?
This is old news. From February.
Aegis raises target on CPRX. Says knew abt Jacobs all along - worry overstated by AF.
http://www.streetinsider.com/Analyst+Comments/Aegis+Boosts+PT+on+Catalyst+Pharma+(CPRX)+to+$5.50%3B+Thinks+Firdapse+Competition+Overstated/8793550.html
The more I think about this article by AF, the more questions I have. But they are all about the intent of the article than anything else.
He has outlined no path through which Jacobus could get the Orphan Drug designation for them selves or how they can stop CPRX. Jacobus is still at the level of phase II trial. CPRX is doing a phase III study. The article's main claim is that the existence of Jacobus is a risk that investors haven't seen. But I see no path through which Jacobus can finish ahead both on the basis of timeline and the capital required to do such work. The main risk to CPRX is the one all investors are (and have been) aware of - that some clinical trials fail. That is it. I think people will come to their senses next week (or at least I hope so).
Authors, especially those who have achieved the power to influence success or failure of stocks (even on a short term basis), should know their position comes with responsibility. There are people at the end of these trades who win or lose. This is not a game. Legitimate questions should be raised of course, but half baked articles that come from an "I do it because I can" attitude are evil. There is nothing substantive in the article that explains the path through which Jacobus poses a risk to CPRX despite that being the core of the message of the article. Every time such issue is broached, AF says something like 'they are working hard to stop cprx'. The question is how? The writer knows he has no answer - that is why he is quiet. This can only be by design in my mind.
Note also that the article says Jacobus has provided the same drug in Europe for free. However BMRN has successfully sold Firdapse drug in Europe with revenues of 12+million last year with year on year growth of 7+%.
FWIW, I averaged down in the 1.90s. I unfortunately used up all my cash at that point and couldn't buy more in the 1.70. Was down thirty some percent at one point, now just 7%. Sometimes patience pays off. $2.25 as I write this.
Even if the 20 year part were true, that says nothing about how many people got the treatment through Jacobus. Was it 5 people, 10 people or 100 people? That would be important information. But it is conveniently overlooked as are other important pieces of information (such as what Jacobus is doing to stop CPRX, what are the odds of success for them? etc. All of which would help investors measure the risk). That is why I say this article is just geared towards stirring up emotions.
BTW, AF doesn't say CPRX will fail in its bid. He has often made calls that are on point. If anything, he says odds of a successful study are high "If the Firdapse study is positive (high odds, see Europe), Catalyst plans to submit the drug for U.S. approval in 2015 and start selling it in 2016."
AF's article is geared to stir emotion.
1. No details on what Jocobus is doing to get approval for itself or to stop CPRX. How one can write Jacobus is doing "stuff" to stop CPRX without giving any details is a mystery to me.
2. CPRX isn't doing these studies for free. That cost has to be recouped. There is value in determining efficacy, safety and creating a drug that is readily available to all patients. Future prices will reflect this fact. The CEO's argument that they can recruit patients despite Jacobus clearly supports the contention that Jacobus can only provide this service to a few. In the article, AF also admits that there is a high odds of approval.
3. This morality play makes no sense to me. Companies are there to make profit by creating value. They are supposed to follow the law. That is all that matters.
I imagine it may take time for this to rebound. CPRX has in recent times increased its institutional investors. Its unlikely this happened without a thorough vetting. It will come back but may take time.
Greetings Waitforit53, Link please?
Every time volume spikes with Genta, there is some PR coming. Have made money on this stock three years, just have to time it right. Play the PR, don't count on the company getting approvals or anything of the sort... My $.02
This company has tremendous potential. I have been buying since 0.0033 ... I know some are hurting here, but good things are coming. As with all good investments patience is key here. Don't plan to time the news. Know what you own and trust your judgement!
What I like about the company in the short term:
The company is in discussions with different buyers including "one of the worlds largest food processors" (see paragraph 5).
The system is patented (see videos in IBOX).
The methodology they use costs a fraction of the alternatives (see presentations on company website).
Management has a successful track record with other startups.
There is a significant need for fast, cost effective ways of identifying microbes.
The system is expandable to meet new challenges or to be customized based on local need (for international markets)
...there are many more positive things for those who want to do their DD.
Remebmer ... Be GREEDY when others are fearful. Look at the orders coming through ... prices are depressed to let the big boys play. This will go up in the long run.
The company has a great product that performs faster and costs less than what is out there currently. It uses classification algorithms which are easy to implement given the substantial computing power today's desktop computers offer. The development of the library against which tests are carried out is the biggest challenge in these applications, and MIT has already done that for several microbes (see slide 13 of the presentation below). Many who are selling do not understand what is behind this technology.
See the presentation posted here:
presentation here
This fell too fast with out cause. Buyers coming back in. We will be back to .01 in no time. Don't fret. Company has great potential. See presentation in previous post. Don't try to time the news. This is going up.
Great presentation here from the company. Dated but shows how well the system works against its competitors. See slides 14-16 specifically for how much value this system has and its accuracy.
http://www.micro-imaging.com/pdf/MIT1000SystemOverview.pdf
Why not invite the President? After all this is about jobs, about small businesses, about energy efficiency --- things he cares about and has run on. SAVW officials should at least try (privately) --- the location isn't even that far away.
Seems like Fibrocell is getting some press in the Russian media. I am down bad on this stock and just reaching for straws of hope I guess. I like the picture they used. Makes for good marketing.
http://www.gazeta.ru/science/2011/07/14_a_3695225.shtml